2012
DOI: 10.1016/j.tibtech.2012.07.004
|View full text |Cite
|
Sign up to set email alerts
|

Towards the miniaturization of GPCR-based live-cell screening assays

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
25
0

Year Published

2013
2013
2021
2021

Publication Types

Select...
4
3
2

Relationship

0
9

Authors

Journals

citations
Cited by 31 publications
(25 citation statements)
references
References 77 publications
0
25
0
Order By: Relevance
“…A related approach is to combine information on the FRET biosensor readouts with spatial and temporal information on cell shape or cell behavior (van Unen et al, 2015a). The combination of FRET biosensors and microfluidics approaches (Martins et al, 2012;Sackmann et al, 2014) can be used to solve more detailed questions around GPCRs by delivering more precisely defined stimulations to cells (for example, repeated stimuli or gradients).…”
Section: Discussionmentioning
confidence: 99%
“…A related approach is to combine information on the FRET biosensor readouts with spatial and temporal information on cell shape or cell behavior (van Unen et al, 2015a). The combination of FRET biosensors and microfluidics approaches (Martins et al, 2012;Sackmann et al, 2014) can be used to solve more detailed questions around GPCRs by delivering more precisely defined stimulations to cells (for example, repeated stimuli or gradients).…”
Section: Discussionmentioning
confidence: 99%
“…Microfluidics and microarray technologies are currently used in this context to monitor cellular signaling in a highly parallelized and automated fashion typically in nano- to picoliter volumes [1], [2]. Downscaling to smaller volumes using intact mammalian cells is not feasible with such approaches.…”
Section: Introductionmentioning
confidence: 99%
“…Cell functional assays represent a higher level of validation for scientific hypothesis and development in biological and biomedical research, and can also be used for clinical disease assessment (Albini and Benelli 2007;Hong and Zu 2013;Kepp et al 2011;Liang et al 2007;Martins et al 2012). In addition to chemotaxis assay as described in this study, we envision that the MS 2 technology can be developed to enable a range of cell functional assays such as cell viability assay, apoptosis assays, cell proliferation assay, cell differentiation assay, cell invasion assay, wound healing assays, cell killing assay, live cell signaling assays, and cell-based organ-on-chip imaging and monitoring.…”
Section: Discussionmentioning
confidence: 99%